



Inari Medical to Participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum

November 6, 2020

IRVINE, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) ("Inari") announced today that its management team will participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020.

About Inari Medical, Inc.

Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTrievers system is 510(k)-cleared by the FDA for the treatment of deep vein thrombosis. The FlowTrievers system is 510(k)-cleared by the FDA for the treatment of pulmonary embolism.

Investor Contact:

Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com